Cellectis Reports Q2 2025 Financial Results: H1 Revenue at $30.2M, $230M Cash Position.

Cellectis reported H1 2025 revenue of $30.2 million, an 89% YoY increase. The company maintains a strong cash position of $230 million, projected to last into H2 2027. End-of-Phase 1 meetings for lasme-cel (UCART22) completed with FDA & EMA; pivotal Phase 2 anticipated in H2 2025. Despite the revenue growth, Cellectis experienced a net loss of $41.9 million, attributed to a $36.1 million change in net financial gain/loss.

Cellectis (NASDAQ:CLLS) has reported its financial results for the first half of 2025, showcasing a significant increase in revenue and maintaining a strong cash position. The company reported consolidated revenues of $30.2 million for H1 2025, representing an 89% year-over-year (YoY) increase from $16.0 million in H1 2024 [1].

The company's cash position stands at $230 million as of June 30, 2025, providing substantial runway into H2 2027. This strong cash position is expected to support the development of the company's pipeline of product candidates, including the manufacturing and clinical trial expenses of lasme-cel (UCART22) and eti-cel (UCART20x22) [1].

One of the key highlights of the quarter was the completion of end-of-Phase 1 meetings with the FDA and EMA for lasme-cel (UCART22) in relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL). Cellectis anticipates initiating a pivotal Phase 2 study in the second half of 2025 [1].

Despite the revenue growth, Cellectis experienced a net loss of $41.9 million for the first half of 2025, compared to a net loss of $19.6 million in the same period last year. This net loss was primarily attributed to a $36.1 million change in net financial gain/loss, which included a one-off gain of $14.3 million in the change in fair value of the derivative instrument component of the Subsequent Investment Agreement with AstraZeneca, offset by a $3.5 million decrease in the change in fair value of warrants issued to the European Investment Bank (EIB) [1].

Cellectis' revenue growth was driven by a $20.0 million increase in revenue recognized under the AstraZeneca Joint Research Collaboration Agreement, partially offset by a slight decrease in other income and a one-off development milestone revenue of $5.4 million recorded last year [1].

The company's research and development (R&D) expenses remained stable at $45.0 million for H1 2025, compared to $45.8 million in H1 2024, primarily due to a decrease in purchases and external expenses and other expenses, offset by an increase in depreciation and amortization expenses and R&D personnel expenses related to non-cash stock-based compensation [1].

In summary, Cellectis reported a strong H1 2025 financial performance with significant revenue growth and a robust cash position. The company's pipeline progress and strategic partnerships, particularly with AstraZeneca, position Cellectis for continued growth in the gene therapy market. However, the company must address the net loss and financial gain/loss changes to improve its overall financial performance.

References:
[1] https://www.stocktitan.net/news/CLLS/cellectis-reports-second-quarter-2025-financial-results-business-6epx8vvbvt3o.html